{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:07:52Z","timestamp":1790039272985,"version":"4.0.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epigenetic dysregulation is a key therapeutic target in pediatric hematologic malignancies resistant to conventional chemotherapy, where allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative option. In this setting, hypomethylating agents (HMAs), such as azacitidine (AZA) and decitabine (DAC), are increasingly used as pre-transplant bridging strategies to reduce disease burden and enhance treatment sensitivity. Their integration with HSCT may improve pre-transplant remission rates, prolong complete remission, and increase the likelihood of durable disease control and cure. However, evidence in pediatric patients remains limited. Here, we performed a systematic review and pooled analysis to evaluate the efficacy of pre-HSCT epigenetic therapy in pediatric hematologic malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A pooled analysis of seven studies of 87 pediatric patients including 51 Myelodysplastic Syndromes (MDS) and 36 Juvenile Myelomonocytic Leukemia (JMML) treated with DAC or AZA prior to HSCT was performed. Statistical analyses used chi-squared or Fisher\u2019s exact tests for categorical variables and non-parametric tests for continuous variables, with correction for multiple comparisons. In MDS, Complete remission (CR) was achieved in 64.7% of patients and strongly associated with DAC, translating into improved post-HSCT survival compared to PD (84.2% vs. 42.8%). In JMML, partial remission (PR) and progressive disease (PD) predominated (47.2% and 41.7%, respectively), while CR was rare (11.1%); response was not associated with HMA type or genetic features, although older age correlated with PD. Comparative analysis confirmed superior responses in MDS (higher CR and SD) versus JMML, which showed higher PR and PD rates. PTPN11 mutations were significantly associated with multiple clinical variables, including treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pre-transplant HMA therapy shows variable efficacy in pediatric myeloid malignancies. DAC induces rapid, deep responses in MDS, improving post-HSCT survival. JMML responds less, yet post-transplant survival remains favorable. Higher HMA responsiveness in MDS likely reflects predominant epigenetic dysregulation, whereas JMML is mainly driven by aberrant RAS\/MAPK pathway activation. These results emphasize that pre-transplant strategies should be tailored to the specific biological and clinical context of each disease. However, their impact relative to upfront HSCT or conventional chemotherapy remains to be definitively determined.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13148-026-02191-0","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:26:35Z","timestamp":1782973595000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Azacitidine and decitabine show distinct response patterns in pediatric Myelodysplastic Syndromes and Juvenile Myelomonocytic Leukemia before HSCT: a systematic review and quantitative analysis"],"prefix":"10.1186","volume":"18","author":[{"given":"Alessandra","family":"Cianflone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Cacace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peppino","family":"Mirabelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco Paolo","family":"Tambaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"issue":"8","key":"2191_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1182\/blood.2019004262","volume":"138","author":"HT Huang","year":"2021","unstructured":"Huang HT, Figueroa ME. Epigenetic deregulation in myeloid malignancies. Blood. 2021;138(8):613\u201324. https:\/\/doi.org\/10.1182\/blood.2019004262.","journal-title":"Blood"},{"issue":"1","key":"2191_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","volume":"20","author":"PA Jones","year":"1980","unstructured":"Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980;20(1):85\u201393. https:\/\/doi.org\/10.1016\/0092-8674(80)90237-8.","journal-title":"Cell"},{"issue":"37","key":"2191_CR3","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","volume":"26","author":"WS Xu","year":"2007","unstructured":"Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26(37):5541\u201352. https:\/\/doi.org\/10.1038\/sj.onc.1210620.","journal-title":"Oncogene"},{"issue":"14","key":"2191_CR4","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1182\/bloodadvances.2020004144","volume":"5","author":"CM Niemeyer","year":"2021","unstructured":"Niemeyer CM, Flotho C, Lipka DB, Star\u00fd J, R\u00f6ssig C, Baruchel A, et al. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021;5(14):2901\u20138. https:\/\/doi.org\/10.1182\/bloodadvances.2020004144.","journal-title":"Blood Adv"},{"issue":"21","key":"2191_CR5","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. J Clin Oncol. 2012;30(21):2670\u20137. https:\/\/doi.org\/10.1200\/JCO.2011.38.9429.","journal-title":"J Clin Oncol"},{"issue":"17","key":"2191_CR6","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood.2019001285","volume":"134","author":"OA O\u2019Connor","year":"2019","unstructured":"O\u2019Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood. 2019;134(17):1395\u2013405. https:\/\/doi.org\/10.1182\/blood.2019001285.","journal-title":"Blood"},{"issue":"20","key":"2191_CR7","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1200\/JCO.2012.44.6823","volume":"31","author":"G Garcia-Manero","year":"2013","unstructured":"Garcia-Manero G, Jabbour E, Borthakur G, Faderl S, Estrov Z, Yang H, et al. Randomized Open-Label Phase II Study of Decitabine in Patients With Low- or Intermediate-Risk Myelodysplastic Syndromes. J Clin Oncol. 2013;31(20):2548\u201353. https:\/\/doi.org\/10.1200\/JCO.2012.44.6823.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2191_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223\u201332. https:\/\/doi.org\/10.1016\/S1470-2045(09)70003-8.","journal-title":"Lancet Oncol"},{"issue":"7","key":"2191_CR9","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1093\/annonc\/mdx154","volume":"28","author":"MT Voso","year":"2017","unstructured":"Voso MT, Leone G, Piciocchi A, Fianchi L, Santarone S, Candoni A, et al. Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. Ann Oncol. 2017;28(7):1547\u201353. https:\/\/doi.org\/10.1093\/annonc\/mdx154.","journal-title":"Ann Oncol"},{"issue":"10","key":"2191_CR10","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.bbmt.2015.05.026","volume":"21","author":"I Pusic","year":"2015","unstructured":"Pusic I, Choi J, Fiala MA, Gao F, Holt M, Cashen AF, et al. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transpl. 2015;21(10):1761\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2015.05.026.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"2191_CR11","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/j.clml.2024.01.012","volume":"24","author":"O Pasvolsky","year":"2024","unstructured":"Pasvolsky O, Saliba R, Popat U, Alousi A, Mehta R, Yeh J, et al. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk. 2024;24(5):e196\u2013204. https:\/\/doi.org\/10.1016\/j.clml.2024.01.012. Located at.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2191_CR12","doi-asserted-by":"publisher","unstructured":"Oran B, de Lima M, Garcia-Manero G et al. A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv. 2020;4(21):5580\u20135588. Blood Adv. 2021;5(6):1755\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2021004374.","DOI":"10.1182\/bloodadvances.2021004374"},{"issue":"1","key":"2191_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13148-017-0411-x","volume":"9","author":"L Gore","year":"2017","unstructured":"Gore L, Triche TJ, Farrar JE, Wai D, Legendre C, Gooden GC, et al. A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML. Clin Epigenetics. 2017;9(1):108. https:\/\/doi.org\/10.1186\/s13148-017-0411-x.","journal-title":"Clin Epigenetics"},{"key":"2191_CR14","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;n71. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"issue":"9","key":"2191_CR15","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (MINORS): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712\u20136. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x.","journal-title":"ANZ J Surg"},{"key":"2191_CR16","unstructured":"[Wickham H, Bryan J. (2025). readxl: Read Excel Files. R package version 1.4.5. https:\/\/github.com\/tidyverse\/readxl, https:\/\/readxl.tidyverse.org"},{"key":"2191_CR17","doi-asserted-by":"crossref","unstructured":"Wickham H. (2016). ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York. ISBN 978-3-319-24277-4. https:\/\/ggplot2.tidyverse.org.","DOI":"10.1007\/978-3-319-24277-4"},{"key":"2191_CR18","unstructured":"Kassambara A. (2023). rstatix: Pipe-Friendly Framework for Basic Statistical Tests. R package version 0.7.2. https:\/\/rpkgs.datanovia.com\/rstatix\/."},{"issue":"5","key":"2191_CR19","doi-asserted-by":"publisher","first-page":"e30931","DOI":"10.1002\/pbc.30931","volume":"71","author":"F Locatelli","year":"2024","unstructured":"Locatelli F, Str\u00e5lin KB, Schmid I, Sevilla J, Smith OP, Van Den Heuvel-Eibrink MM, et al. Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA\u2010JMML\u2010001 trial. Pediatr Blood Cancer. 2024;71(5):e30931. https:\/\/doi.org\/10.1002\/pbc.30931.","journal-title":"Pediatr Blood Cancer"},{"issue":"14","key":"2191_CR20","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1182\/blood-2015-01-619734","volume":"125","author":"A Cseh","year":"2015","unstructured":"Cseh A, Niemeyer CM, Yoshimi A, Dworzak M, Hasle H, Van Den Heuvel-Eibrink MM, et al. Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group. Blood. 2015;125(14):2311\u20133. https:\/\/doi.org\/10.1182\/blood-2015-01-619734.","journal-title":"Blood"},{"issue":"12","key":"2191_CR21","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.3324\/haematol.2016.145821","volume":"101","author":"N Waespe","year":"2016","unstructured":"Waespe N, Van Den Akker M, Klaassen RJ, Lieberman L, Irwin MS, Ali SS, et al. Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation. Haematologica. 2016;101(12):1508\u201315. https:\/\/doi.org\/10.3324\/haematol.2016.145821.","journal-title":"Haematologica"},{"issue":"1","key":"2191_CR22","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12887-022-03376-1","volume":"22","author":"J Gao","year":"2022","unstructured":"Gao J, Hu Y, Gao L, Xiao P, Lu J, Hu S. The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years\u2019 experience of a single center. BMC Pediatr. 2022;22(1):312. https:\/\/doi.org\/10.1186\/s12887-022-03376-1.","journal-title":"BMC Pediatr"},{"issue":"1","key":"2191_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12185-022-03457-y","volume":"117","author":"Y Cai","year":"2023","unstructured":"Cai Y, Zhang J, Yi M, Zhang W, Liu X, Zhang X, et al. Short-term efficacy of decitabine-based therapy in JMML: a retrospective study from a single center in China. Int J Hematol. 2023;117(1):121\u20137. https:\/\/doi.org\/10.1007\/s12185-022-03457-y.","journal-title":"Int J Hematol"},{"issue":"4","key":"2191_CR24","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00277-024-05628-9","volume":"103","author":"Y Ren","year":"2024","unstructured":"Ren Y, Liu F, Chen X, Zhang X, Zhao B, Wan Y, et al. Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2024;103(4):1345\u201351. https:\/\/doi.org\/10.1007\/s00277-024-05628-9.","journal-title":"Ann Hematol"},{"issue":"19","key":"2191_CR25","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019\u201332. https:\/\/doi.org\/10.1182\/blood-2011-01-293050.","journal-title":"Blood"},{"key":"2191_CR26","doi-asserted-by":"publisher","unstructured":"Arber DA, Orazi A, Hasserjian R et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u20132405. Blood. 2016;128(3):462\u20133. https:\/\/doi.org\/10.1182\/blood-2016-06-721662.","DOI":"10.1182\/blood-2016-06-721662"},{"issue":"1","key":"2191_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00428-022-03447-9","volume":"482","author":"M Rudelius","year":"2023","unstructured":"Rudelius M, Weinberg OK, Niemeyer CM, Shimamura A, Calvo KR. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia. Virchows Arch. 2023;482(1):113\u201330. https:\/\/doi.org\/10.1007\/s00428-022-03447-9.","journal-title":"Virchows Arch"},{"issue":"2","key":"2191_CR28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/sj.leu.2402765","volume":"17","author":"H Hasle","year":"2003","unstructured":"Hasle H, Niemeyer CM, Chessells JM, Baumann I, Bennett JM, Kerndrup G, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17(2):277\u201382. https:\/\/doi.org\/10.1038\/sj.leu.2402765.","journal-title":"Leukemia"},{"issue":"3","key":"2191_CR29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1515\/jtim-2017-0002","volume":"5","author":"M Hong","year":"2017","unstructured":"Hong M, He G. The 2016 revision to the World Health Organization classification of myelodysplastic syndromes. J Transl Intern Med. 2017;5(3):139\u201343. https:\/\/doi.org\/10.1515\/jtim-2017-0002.","journal-title":"J Transl Intern Med"},{"issue":"11","key":"2191_CR30","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140(11):1200\u201328. https:\/\/doi.org\/10.1182\/blood.2022015850.","journal-title":"Blood"},{"issue":"2","key":"2191_CR31","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419\u201325. https:\/\/doi.org\/10.1182\/blood-2005-10-4149.","journal-title":"Blood"},{"issue":"1","key":"2191_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3324\/haematol.2014.109892","volume":"100","author":"CM Niemeyer","year":"2015","unstructured":"Niemeyer CM, Loh ML, Cseh A, Cooper T, Dvorak CC, Chan R, et al. Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. Haematologica. 2015;100(1):17\u201322. https:\/\/doi.org\/10.3324\/haematol.2014.109892.","journal-title":"Haematologica"},{"issue":"7","key":"2191_CR33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/08880018.2020.1767244","volume":"37","author":"MA Wajid","year":"2020","unstructured":"Wajid MA, Gupta AK, Das G, Sahoo D, Meena JP, Seth R. Outcomes of juvenile myelomonocytic leukemia patients after sequential therapy with cytarabine and 6-mercaptopurine. Pediatr Hematol Oncol. 2020;37(7):573\u201381. https:\/\/doi.org\/10.1080\/08880018.2020.1767244.","journal-title":"Pediatr Hematol Oncol"},{"issue":"3","key":"2191_CR34","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.htct.2018.05.013","volume":"40","author":"SMM Magalh\u00e3es","year":"2018","unstructured":"Magalh\u00e3es SMM, Chauffaille MDLLF, Velloso EDRP, Buzzini R, Bernardo WM. Part 5: Myelodysplastic syndromes\u2014Treatment of high-risk disease. Hematol Transfus Cell Ther. 2018;40(3):278\u201382. https:\/\/doi.org\/10.1016\/j.htct.2018.05.013.","journal-title":"Hematol Transfus Cell Ther"},{"key":"2191_CR35","doi-asserted-by":"publisher","unstructured":"Kr\u00f6ger N. Treatment of high risk myelodysplastic syndrome. Haematol 2024 Dec 5. https:\/\/doi.org\/10.3324\/haematol.2023.284946.","DOI":"10.3324\/haematol.2023.284946"},{"issue":"11","key":"2191_CR36","doi-asserted-by":"publisher","first-page":"e27948","DOI":"10.1002\/pbc.27948","volume":"66","author":"A Hecht","year":"2019","unstructured":"Hecht A, Meyer J, Chehab FF, White KL, Magruder K, Dvorak CC, et al. Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia. Pediatr Blood Cancer. 2019;66(11):e27948. https:\/\/doi.org\/10.1002\/pbc.27948.","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"2191_CR37","doi-asserted-by":"publisher","first-page":"e9001","DOI":"10.1371\/journal.pone.0009001","volume":"5","author":"PW Hollenbach","year":"2010","unstructured":"Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE. 2010;5(2):e9001. https:\/\/doi.org\/10.1371\/journal.pone.0009001 . PubMed PMID: 20126405; PubMed Central PMCID: PMC2814859.","journal-title":"PLoS ONE"},{"key":"2191_CR38","first-page":"119","volume":"1","author":"AN Nguyen","year":"2010","unstructured":"Nguyen AN, Hollenbach PW, Richard N, Luna-Moran A, Brady H, Heise C, et al. Azacitidine and decitabine have different mechanisms of action in non-small cell lung cancer cell lines. Lung Cancer. 2010;1:119\u201340. 10.2147. \/LCTT.S11726 PubMed PMID: 28210112; PubMed Central PMCID: PMC5312472.","journal-title":"Lung Cancer"},{"issue":"26","key":"2191_CR39","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","volume":"364","author":"R Bejar","year":"2011","unstructured":"Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical Effect of Point Mutations in Myelodysplastic Syndromes. N Engl J Med. 2011;364(26):2496\u2013506. https:\/\/doi.org\/10.1056\/NEJMoa1013343.","journal-title":"N Engl J Med"},{"issue":"1","key":"2191_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/sj.leu.2401240","volume":"13","author":"C Flotho","year":"1999","unstructured":"Flotho C, Valcamonica S, Mach-Pascual S, Schmahl G, Corral L, Ritterbach J, et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia. 1999;13(1):32\u20137. https:\/\/doi.org\/10.1038\/sj.leu.2401240.","journal-title":"Leukemia"},{"issue":"1","key":"2191_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/ng0116-101a","volume":"48","author":"E Stieglitz","year":"2016","unstructured":"Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, et al. Correction: Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2016;48(1):101\u2013101. https:\/\/doi.org\/10.1038\/ng0116-101a.","journal-title":"Nat Genet"},{"issue":"11","key":"2191_CR42","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/ng.3420","volume":"47","author":"A Caye","year":"2015","unstructured":"Caye A, Strullu M, Guidez F, Cassinat B, Gazal S, Fenneteau O, et al. Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Nat Genet. 2015;47(11):1334\u201340. https:\/\/doi.org\/10.1038\/ng.3420.","journal-title":"Nat Genet"},{"issue":"17","key":"2191_CR43","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","volume":"124","author":"R Bejar","year":"2014","unstructured":"Bejar R, Lord A, Stevenson K, Bar-Natan M, P\u00e9rez-Ladaga A, Zaneveld J, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705\u201312. https:\/\/doi.org\/10.1182\/blood-2014-06-582809.","journal-title":"Blood"},{"key":"2191_CR44","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/S0145-2126(09)70228-0","volume":"33","author":"DP Steensma","year":"2009","unstructured":"Steensma DP. Decitabine treatment of patients with higher-risk myelodysplastic syndromes. Leuk Res. 2009;33:S12\u20137. https:\/\/doi.org\/10.1016\/S0145-2126(09)70228-0.","journal-title":"Leuk Res"},{"issue":"6","key":"2191_CR45","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40272-023-00588-5","volume":"25","author":"A Rubio-San-Sim\u00f3n","year":"2023","unstructured":"Rubio-San-Sim\u00f3n A, Van Eijkelenburg NKA, Hoogendijk R, Hasle H, Niemeyer CM, Dworzak MN, et al. Azacitidine (Vidaza\u00ae) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I\/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015). Pediatr Drugs. 2023;25(6):719\u201328. https:\/\/doi.org\/10.1007\/s40272-023-00588-5.","journal-title":"Pediatr Drugs"},{"issue":"1","key":"2191_CR46","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.clml.2014.04.010","volume":"15","author":"M Xie","year":"2015","unstructured":"Xie M, Jiang Q, Xie Y. Comparison Between Decitabine and Azacitidine for the Treatment of Myelodysplastic Syndrome: A Meta-Analysis With 1392 Participants. Clin Lymphoma Myeloma Leuk. 2015;15(1):22\u20138. https:\/\/doi.org\/10.1016\/j.clml.2014.04.010.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2191_CR47","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","volume":"35","author":"J Stomper","year":"2021","unstructured":"Stomper J, Rotondo JC, Greve G, L\u00fcbbert M. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021;35(7):1873\u201389. https:\/\/doi.org\/10.1038\/s41375-021-01218-0.","journal-title":"Leukemia"},{"key":"2191_CR48","doi-asserted-by":"publisher","first-page":"1426640","DOI":"10.3389\/fimmu.2024.1426640","volume":"15","author":"Z Peng","year":"2024","unstructured":"Peng Z, Gao J, Huang L, He Y, Tang H, Zong S, et al. Decitabine-based treatment strategy improved the outcome of HSCT in JMML: a retrospective cohort study. Front Immunol. 2024;15:1426640. https:\/\/doi.org\/10.3389\/fimmu.2024.1426640.","journal-title":"Front Immunol"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-026-02191-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02191-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02191-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:37:36Z","timestamp":1790037456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13148-026-02191-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2191"],"URL":"https:\/\/doi.org\/10.1186\/s13148-026-02191-0","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"169"}}